Image courtesy of Lantheus
January 30, 2015 — Lantheus Medical Imaging Inc. announced an agreement with the Institute for Radioelements (IRE) for the future supply of Xenon Xe 133 Gas (Xenon 133). Currently, Lantheus is the only U.S. manufacturer of Xenon 133, which is an inhaled radiopharmaceutical imaging agent used for the evaluation of pulmonary function and for imaging the lungs, as well as the assessment of cerebral blood flow.
Under the terms of the agreement, IRE will provide bulk Xenon 133 to Lantheus for processing and finishing, once development work has been completed and all necessary regulatory approvals have been obtained. Lantheus estimates commercial production will occur in 2016.
For more information: www.lantheus.com, www.ire.eu
July 30, 2024 
